Provided are a dihydronaphthyridinone compound as shown in formula (I), which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. In addition, provided are a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.
提供了一种二
氢萘啉
酮化合物,如式(I)所示,该化合物对RIPK1具有选择性抑制作用,以及其药学上可接受的盐、立体异构体、溶剂化物或前药。此外,还提供了含有该化合物的制药组合物,并将其用于制备治疗RIPK1相关疾病或症状的药物。